These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 20847097)

  • 21. Fetuin-A is associated with calcified coronary artery disease.
    Mori K; Ikari Y; Jono S; Emoto M; Shioi A; Koyama H; Shoji T; Ishimura E; Inaba M; Hara K; Nishizawa Y
    Coron Artery Dis; 2010 Aug; 21(5):281-5. PubMed ID: 20436350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What does the circulating AHSG/fetuin-A level tell us?
    Kazama JJ
    Clin Exp Nephrol; 2007 Dec; 11(4):336-337. PubMed ID: 18085398
    [No Abstract]   [Full Text] [Related]  

  • 23. Supplementing creatinine-based estimates of risk in chronic kidney disease: is it time?
    Tonelli M; Manns B
    JAMA; 2011 Apr; 305(15):1593-5. PubMed ID: 21482745
    [No Abstract]   [Full Text] [Related]  

  • 24. Is CT the better angiogram? Coronary interventions and CT imaging.
    Achenbach S; Ludwig J
    JACC Cardiovasc Imaging; 2010 Jan; 3(1):29-31. PubMed ID: 20129527
    [No Abstract]   [Full Text] [Related]  

  • 25. Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease.
    van Husen M; Fischer AK; Lehnhardt A; Klaassen I; Möller K; Müller-Wiefel DE; Kemper MJ
    Kidney Int; 2010 Jul; 78(2):200-6. PubMed ID: 20407479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can contrast-induced nephropathy after percutaneous coronary intervention be accurately predicted with a risk score?
    Marenzi G
    Nat Clin Pract Cardiovasc Med; 2005 Feb; 2(2):80-1. PubMed ID: 16265376
    [No Abstract]   [Full Text] [Related]  

  • 27. FGF23: is it ready for prime time?
    Wesseling-Perry K
    Clin Chem; 2011 Nov; 57(11):1476-7. PubMed ID: 21914788
    [No Abstract]   [Full Text] [Related]  

  • 28. Angiography for ESRD transplant evaluation: "nuclear" or "unclear" imaging versus angiography.
    Tobis J
    Catheter Cardiovasc Interv; 2010 Nov; 76(6):802-3. PubMed ID: 21104729
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical utility of serum cystatin C in predicting coronary artery disease.
    Koc M; Batur MK; Karaarslan O; Abali G
    Cardiol J; 2010; 17(4):374-80. PubMed ID: 20690093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Markers of mineral metabolism and cardiovascular disease.
    Everett BM
    Ann Intern Med; 2010 May; 152(10):683-4. PubMed ID: 20479031
    [No Abstract]   [Full Text] [Related]  

  • 31. Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo.
    Finn AV; Oh JS; Hendricks M; Daher M; Cagliero E; Byrne RM; Nadelson J; Crimins J; Kastrati A; Schömig A; Bruskina O; Palacios I; John MC; Gold HK
    Am Heart J; 2009 Feb; 157(2):383.e1-8. PubMed ID: 19185649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cystatin C and risk of mortality among patients undergoing percutaneous coronary intervention.
    Angeli F; Verdecchia P; Savonitto S; Arraiz G; Zaninotto M; Broccatelli A; Cosma C; De Servi S; Sabino F; Briguori C; Ambrosio G; Cavallini C;
    EuroIntervention; 2015 Nov; 11(7):757-64. PubMed ID: 25136879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Source matters: from phosphorus load to bioavailability.
    Fukagawa M; Komaba H; Miyamoto K
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):239-40. PubMed ID: 21292849
    [No Abstract]   [Full Text] [Related]  

  • 34. Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease.
    Arroyo-Espliguero R; Avanzas P; Quiles J; Kaski JC
    Atherosclerosis; 2009 May; 204(1):239-43. PubMed ID: 18823889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal function and risk stratification of diabetic and nondiabetic patients undergoing evaluation for coronary artery disease.
    Hakeem A; Bhatti S; Karmali KN; Dillie KS; Cook JR; Xu J; Samad Z; Chang SM
    JACC Cardiovasc Imaging; 2010 Jul; 3(7):734-45. PubMed ID: 20633852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Images beyond clinical presentation? Promising, but not confirmed in ESRD transplant candidates.
    Sosnowski M
    Cardiol J; 2010; 17(4):327-9. PubMed ID: 20690086
    [No Abstract]   [Full Text] [Related]  

  • 37. The adverse long-term impact of renal impairment in patients undergoing percutaneous coronary intervention in the drug-eluting stent era.
    Appleby CE; Ivanov J; Lavi S; Mackie K; Horlick EM; Ing D; Overgaard CB; Seidelin PH; von Harsdorf R; Dzavík V
    Circ Cardiovasc Interv; 2009 Aug; 2(4):309-16. PubMed ID: 20031733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical prediction of obstructive coronary disease in patients referred for coronary CTA: "low-hanging fruit" or still a "risky business"?
    Abidov A
    J Cardiovasc Comput Tomogr; 2009; 3(6):392-3. PubMed ID: 20083059
    [No Abstract]   [Full Text] [Related]  

  • 39. Inflammatory parameters are independent predictors of severe epicardial coronary stenosis in asymptomatic diabetic patients with silent myocardial ischemia.
    Piot C; Fontbonne A; Sultan A; Rasamisoa M; Mariano-Goulart D; Davy JM; Monnier L; Avignon A
    Diabetes Care; 2003 Feb; 26(2):545-6. PubMed ID: 12547901
    [No Abstract]   [Full Text] [Related]  

  • 40. Parameters for coronary plaque vulnerability assessed with multidetector computed tomography and intracoronary ultrasound correlation.
    Pugliese F; Meijboom WB; Ligthart J; La Grutta L; Vourvouri EC; Rodriguez-Granillo G; Mollet NR; Krestin GP; de Feyter PJ; Cademartiri F
    J Cardiovasc Med (Hagerstown); 2009 Nov; 10(11):821-6. PubMed ID: 20081565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.